Patents by Inventor Derek Turner

Derek Turner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7728127
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: June 1, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Patent number: 7713931
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: May 11, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Patent number: 7695522
    Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer may be grown from the metal substrate, by anodizing, and the biocidal material incorporated in it by ion exchange. Alternatively the layer may be deposited by electroplating, followed by diffusion bonding so as to become integral with the metal substrate. In either case, silver is a suitable biocidal material; and both the release rate and the quantity of biocidal material should be low to avoid toxic effects on body cells. Electropolishing the surface before formation of the surface layer is also beneficial, and this may be achieved by electropolishing.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: April 13, 2010
    Assignee: Accentus plc
    Inventors: Martin Edward Lee Pickford, Andrew Derek Turner
  • Patent number: 7677890
    Abstract: A dental handpiece is disclosed including a turbine construction creating a radial in flow of air onto the impeller blades about the whole circumference of the turbine. This generates additional torque and avoids asymmetrical thrust on the impeller wheel. A pair of axially spaced air bearings support the turbine. Air supply to the bearings is controlled in such a way that the air bearings are floated before drive air is supplied to the turbine and after drive air to the turbine has been shut off. This ensures that the air bearings are always operational irrespective of the operational state of the turbine. The handpiece has an improved ergonomic shape, especially the shape and configuration of the front or drive head, which provides additional tooth clearance and a better field of view. An angled swivel connection to the umbilical cord is provided which reduces physical strain on the dentist's wrist.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: March 16, 2010
    Assignee: TTI Turner Technology Instruments Inc.
    Inventor: Derek Turner
  • Publication number: 20100036501
    Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer may be grown from the metal substrate, by anodising, and the biocidal material incorporated in it by ion exchange. Alternatively the layer may be deposited by electroplating, followed by diffusion bonding so as to become integral with the metal substrate. In either case, silver is a suitable biocidal material; and both the release rate and the quantity of biocidal material should be low to avoid toxic effects on body cells. Electropolishing the surface before formation of the surface layer is also beneficial, and this may be achieved by electropolishing.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Applicant: ACCENTUS PLC
    Inventors: Martin Edward Lee Pickford, Andrew Derek Turner
  • Publication number: 20100032309
    Abstract: A metal implant for use in a surgical procedure is provided with a surface layer that is integral with the metal substrate, and which incorporates a biocidal material. The surface layer may be grown from the metal substrate, by anodising, and the biocidal material incorporated in it by ion exchange. Alternatively the layer may be deposited by electroplating, followed by diffusion bonding so as to become integral with the metal substrate. In either case, silver is a suitable biocidal material; and both the release rate and the quantity of biocidal material should be low to avoid toxic effects on body cells. Electropolishing the surface before formation of the surface layer is also beneficial, and this may be achieved by electropolishing.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Applicant: ACCENTUS PLC
    Inventors: Martin Edward Lee Pickford, Andrew Derek Turner
  • Patent number: 7655621
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: February 2, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Patent number: 7649080
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: January 19, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Patent number: 7612037
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: November 3, 2009
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel D. Long, Daniel Marquess, Edmund J. Moran, Matthew B. Nodwell, S. Derek Turner, James Aggen
  • Patent number: 7601690
    Abstract: This invention provides cross-linked glycopeptides—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: October 13, 2009
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Patent number: 7592355
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: September 22, 2009
    Assignee: Theravance, Inc.
    Inventors: Daniel Marquess, Paul R. Fatheree, S. Derek Turner, Daniel D. Long
  • Publication number: 20090198344
    Abstract: An implant with a metal structure for use in a surgical procedure, in which at a region of the implant to be in contact with bone the metal structure is provided with a roughened surface. The roughened region is then provided with a ceramic coating comprising hydroxyapatite by a thermal spraying process. Biocidal ions of silver are absorbed into the ceramic coating, and gradually leach out into body fluids after implantation. The hydroxyapatite enhances bone regrowth into the implant, while the silver ions suppress infection.
    Type: Application
    Filed: June 11, 2007
    Publication date: August 6, 2009
    Applicant: Accentus PLC
    Inventors: Thomas Campbell Prentice, Martin Edward Lee Pickford, David Richard Lewis, Andrew Derek Turner
  • Patent number: 7553962
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: June 30, 2009
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Publication number: 20090137460
    Abstract: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 19, 2008
    Publication date: May 28, 2009
    Inventors: Daniel Marquess, Martin S. Linsell, S. Derek Turner, Sean G. Trapp, Daniel D. Long, Paul R. Fatheree
  • Patent number: 7534889
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: May 19, 2009
    Assignee: Theravance, Inc.
    Inventors: Seok-Ki Choi, Paul Fatheree, Adam A Goldblum, Lan Jiang, Daniel D Long, Daniel Marquess, S. Derek Turner
  • Publication number: 20090036483
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: September 22, 2008
    Publication date: February 5, 2009
    Inventors: Adam A. Goldblum, Seok-ki Choi, Paul R. Fatheree, Roland Gendron, Lan Jiang, Daniel D. Long, Daniel Marquess, S. Derek Turner
  • Patent number: 7446114
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: November 4, 2008
    Assignee: Theravance, Inc.
    Inventors: Adam A. Goldblum, Seok-ki Choi, Paul R. Fatheree, Roland Gendron, Lan Jiang, Daniel D. Long, Daniel Marquess, S. Derek Turner
  • Publication number: 20080255187
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 11, 2008
    Publication date: October 16, 2008
    Inventors: Seok-Ki Choi, Paul Fatheree, Adam A. Goldblum, Lan Jiang, Daniel D. Long, Daniel Marquess, S. Derek Turner
  • Patent number: 7419989
    Abstract: The invention provides novel indazole-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: September 2, 2008
    Assignee: Theravance, Inc.
    Inventors: Paul Fatheree, Roland Gendron, Adam A Goldblum, Daniel D Long, Daniel Marquess, S. Derek Turner, Seok-Ki Choi
  • Publication number: 20080194464
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: August 24, 2007
    Publication date: August 14, 2008
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel D. Long, Daniel Marquess, Edmund J. Moran, Matthew B. Nodwell, S. Derek Turner, James Aggen